Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study.
Hans-Peter HartungR MallickV BrilR A LewisSatomi MitsuhashiJ-P LawoO MielkeB L DurnD R CornblathI S J MerkiesI N van Schaiknull nullPublished in: European journal of neurology (2019)
IgPro20 maintained or improved QOL in most subjects with CIDP, consistent with the PATH study findings that both IgPro20 doses were efficacious in maintaining CIDP.